A Simple Key For BCAT-IN-4 Unveiled
MI-CP151 was a stage 1b randomised, double-blind, placebo managed, dose-escalation, multicentre examine to evaluate many intravenous doses of sifalimumab, in adult patients with dermatomyositis or polymyositis (NCT00533091). Key trial aims had been To judge the safety and tolerability of sifalimumab in dermatomyositis or polymyositis clients, whils